Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

Brian Lawlor; Ricardo Segurado; Seán Kennelly; Marcel G. M. Olde Rikkert; Robert Howard

doi:10.1371/journal.pmed.1002660

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

Brian Lawlor, Ricardo Segurado, Seán Kennelly, Marcel G. M. Olde Rikkert, Robert Howard, Florence Pasquier, Anne Börjesson‐Hanson, Magda Tsolaki, Ugo Lucca, D. William Molloy, Robert F. Coen, Matthias W. Riepe, János Kálmán, Rose Anne Kenny, Fiona Cregg...

Public Library of Science (2018) • Volume 15, Issue 9, Pages e1002660-e1002660

PDF Available

Abstract

Clinicaltrials.gov NCT02017340, EudraCT number 2012-002764-27.

Quick Actions

Read Full Paper

Publication Info

DOI

10.1371/journal.pmed.1002660

Language

English

Topic

Dementia and Cognitive Impairment Research

Keywords

Medicine, Dementia, Placebo, Clinical Dementia Rating, Alzheimer's disease, Cognitive decline, Population, Clinical trial, Internal medicine, Stroke (engine), Disease, Physical therapy, Pediatrics, Pathology

Published

September 24, 2018

Citations

193 citations

FWCI

25.12

External Resources

DOI Link OpenAlex

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

Abstract

Quick Actions

Publication Info

External Resources

Suggested Papers

Radiopharmaceuticals and their applications in medicine

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Polo-like Kinase-1 Controls Recovery from a G2 DNA Damage-Induced Arrest in Mammalian Cells

Suggested Papers

Suggested Papers

Radiopharmaceuticals and their applications in medicine

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Polo-like Kinase-1 Controls Recovery from a G2 DNA Damage-Induced Arrest in Mammalian Cells